Company Overview and News

 
Muthoot Finance Limited - Allotment of ESOP/ESPS

14h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MUTHOOTFIN 533398

 
DCM Shriram, Tata Steel, Union Bank, Muthoot Finance top gainers among BSE Group A stocks

15h moneycontrol
The Indian stock market has turned negative this Wednesday with the Nifty50 down 50 points and is trading at 11,228 while the Sensex is trading lower by 185 points at 37,104.
UBNC MUTHOOTFIN MONSANTO GESHIP HFCL 533398 500183 500470 TTST TATASTEEL TATLY 524084 500620 DCMSHRIRAM 523367

 
D-Street Buzz: Nifty metal outperforms led by JSW Steel; Dish TV down 6%, BoB most active

18h moneycontrol
The Indian benchmark indices continues to trade on a positive note this Wednesday afternoon with the Nifty50 up 21 points and is trading at 11,300 while the Sensex is trading higher by 53 points at 37,343.
HINDCOPPER KOHINOOR MUTHOOTFIN PGEL 500325 500228 RELIANCE 532617 HNDZY HFCL 533398 NAUKRI 532777 533137 HCL-INSYS DEN 532221 500470 SONATSOFTW RIGD 500179 JSL GAILF BEL RLNIY SBAZ BHQRY HINDALCO 532508 533581 513599 JETAIRWAYS JSWSTEEL 533104 512559 HNDNF 500183 TTST TATASTEEL TATLY GAILY DCMSHRIRAM 500049 GLOBUSSPR 500440 500188 HINDZINC 523367

 
Muthoot Finance shares jump 10.5% as Q1 net rises

2018-09-05 livemint
New Delhi: Shares of Muthoot Finance (MFIN) Wednesday surged 10.5% after the company registered a rise of 43% in consolidated net profit for April-June, 2018-19.
MUTHOOTFIN 533398

 
Muthoot Finance Q1 net rises 43% to Rs 492 crore

2018-09-05 moneycontrol
Muthoot Finance (MFIN) Wednesday registered a rise of 43 percent in its consolidated net profit at Rs 492 crore in first quarter ended June of the current fiscal. The company had recorded a net profit of Rs 345 crore in the same quarter of 2017-18.
MUTHOOTFIN AAF 533398

 
Muthoot Finance, Advanced Enzyme, Cyient, Reliance Infra top gainers among BSE #39;A#39; group stocks

2018-09-05 moneycontrol
The Indian market extended the morning losses in the afternoon with the Nifty50 trading at 11,455, down 65 points and the Sensex trading 210 points lower at 37,947.
MUTHOOTFIN RELEY CREST RIFS RELFF 517506 533398 500390 RELINFRA 532234 TTKPRESTIG 511413 RIFA NATIONALUM

 
Muthoot Finance jumps to 7-month high

2018-09-05 thehindubusinessline
Gold financing company Muthoot Finance jumped as much as 7.5 per cent to Rs 429.70, in its biggest intraday percentage gain since February 8.
MUTHOOTFIN 532617 JETAIRWAYS 533398

 
D-Street Buzz: Nifty pharma outperforms with Sun Pharma up 2%; RIL advances, Advanced Enzyme jumps 9%

2018-09-05 moneycontrol
The Indian benchmark indices are trading on a flat to positive note this Wednesday morning with the Nifty50 trading at 11,521, up 1 point while the Sensex is trading higher by 38 points at 38,196.
ESL SUZLON MUTHOOTFIN 500325 AUROPHARMA RELIANCE 533398 TATACOMM 532733 CADILAHC CSLQY 532321 532221 SONATSOFTW RIGD AJANTPHARM 520086 GAILF BEL SUEL SUNTV RLNIY 500870 BHQRY 524804 533264 532667 CDLYY CASTROLIND 532331 ARBQY GAILY SICAL SNQVY 500049 500483

 
Muthoot Finance gains 9% on better June quarter result, to raise Rs 5,000cr

2018-09-05 moneycontrol
Share price of Muthoot Finance gained 9 percent intraday Wednesday on the back of robust June quarter numbers and fund raising plan.
MUTHOOTFIN 533398

 
Muthoot Finance Limited - AGM/Book Closure

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MUTHOOTFIN 533398

 
Muthoot Finance Limited - Shareholders meeting

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
MUTHOOTFIN 533398

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...